CBIO
CRESCENT BIOPHARMA, INC.
Latest Form 4:Purchase$12.4MbyFairmount Funds Management LLC (Director, 10% Owner) · filed Jul 20, 2026
CRESCENT BIOPHARMA, INC. (CBIO) has 16 SEC Form 4 filings (24 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jul 20, 2026.
Insiders have net bought $11.1M over the trailing 6 months. The largest single insider purchase in this window was $12.4M by Director, 10% Owner Fairmount Funds Management LLC on Jul 16, 2026.
- Industry:Biotechnology
- CEO:Joshua T. Brumm
- Employees:44
- HQ:Waltham, MA, US
- IPO:2014-01-10
Insider Buying
$12.4M
reported purchases (SEC code P)
Insider Selling
$1.2M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$472.6M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director, 10% Owner | Purchase | 853,450 | $12.4M | Jul 20 | SEC ↗ | |
Im Ellie EunkyungFirst filing | Chief Medical Officer | Sale | 1,219 | $22K | Jun 23 | SEC ↗ |
Bispham Barbara HarlinFirst filing | See Remarks | Sale | 1,218 | $22K | Jun 23 | SEC ↗ |
Lynch RyanFirst filing | See Remarks | Sale | 465 | $8K | Jun 23 | SEC ↗ |
Scalzo Richard WilliamFirst filing | Chief Financial Officer | Sale | 1,112 | $20K | Jun 23 | SEC ↗ |
McNeill JonathanFirst filing | President and COO | Sale | 20,549 | $370K | Jun 23 | SEC ↗ |
Brumm Joshua TFirst filing | Chief Executive Officer | Sale | 42,305 | $761K | Jun 23 | SEC ↗ |
Pinkas JanFirst filing | Chief Scientific Officer | Sale | 1,288 | $23K | Jun 23 | SEC ↗ |
Related companies
CRESCENT BIOPHARMA, INC. is in the Healthcare sector.